DK0724581T3 - Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf - Google Patents

Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf

Info

Publication number: DK0724581T3
Authority: DK; Denmark
Prior art keywords: mycophenolate mofetil; crystalline anhydrous; intravenous formulation; anhydrous mycophenolate; crystalline
Prior art date: 1993-09-15

Application number

DK94928054T

Other languages

English (en)

Inventor

Jeffrey S Fleitman

Roger Cherng Fu

De-Mei Leung

Michele C Rizzolio

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-15

Filing date

1994-09-12

Publication date

1999-08-02

1994-09-12 Application filed by Syntex Inc filed Critical Syntex Inc

1999-08-02 Application granted granted Critical

1999-08-02 Publication of DK0724581T3 publication Critical patent/DK0724581T3/da

Links

238000009472 formulation Methods 0.000 title abstract 2
238000001990 intravenous administration Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 title abstract 2
229960004866 mycophenolate mofetil Drugs 0.000 title abstract 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
150000001450 anions Chemical class 0.000 abstract 1
230000000536 complexating effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Furan Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DK94928054T 1993-09-15 1994-09-12 Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf DK0724581T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12184193A	1993-09-15	1993-09-15
PCT/US1994/010142 WO1995007902A1 (en)	1993-09-15	1994-09-12	Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Publications (1)

Publication Number	Publication Date
DK0724581T3 true DK0724581T3 (da)	1999-08-02

Family

ID=22399119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94928054T DK0724581T3 (da)	1993-09-15	1994-09-12	Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf

Country Status (31)

Country	Link
US (2)	US5543408A (da)
EP (1)	EP0724581B1 (da)
JP (1)	JP3411038B2 (da)
KR (1)	KR100349772B1 (da)
CN (1)	CN1060770C (da)
AT (1)	ATE173475T1 (da)
AU (1)	AU677435B2 (da)
BR (1)	BR9407469A (da)
CA (1)	CA2171836C (da)
CZ (1)	CZ292423B6 (da)
DE (1)	DE69414720T2 (da)
DK (1)	DK0724581T3 (da)
ES (1)	ES2123831T3 (da)
FI (1)	FI119639B (da)
HU (1)	HU217300B (da)
IL (1)	IL110970A (da)
LT (1)	LT4052B (da)
LV (1)	LV11326B (da)
MX (1)	MXPA94007099A (da)
NO (1)	NO314727B1 (da)
NZ (1)	NZ273801A (da)
PH (1)	PH30685A (da)
PL (1)	PL178522B1 (da)
RO (2)	RO118075B1 (da)
RU (1)	RU2132849C1 (da)
SG (1)	SG55006A1 (da)
SI (1)	SI9420052B (da)
TW (1)	TW370527B (da)
UA (1)	UA49797C2 (da)
WO (1)	WO1995007902A1 (da)
ZA (1)	ZA947088B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation
IN188985B (da) *	1998-12-09	2002-11-30	Biocon Ltd
CZ292123B6 (cs) *	2001-06-08	2003-08-13	Ivax Pharmaceuticals S.R.O.	Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds
GB0307553D0 (en) *	2003-04-01	2003-05-07	Novartis Ag	Organic compounds
US20050187170A1 (en) *	2003-06-16	2005-08-25	Biocryst Pharmaceuticals, Inc.	Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
ES2308226T3 (es) *	2003-09-11	2008-12-01	Sandoz Ag	Proceso para la produccion de micofenolato mofetil.
MXPA06005659A (es) *	2004-04-26	2007-04-10	Teva Gyogyszergyar Zartkoruen	Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
WO2005105771A1 (en) *	2004-04-27	2005-11-10	Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg	Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
US20060069150A1 (en) *	2004-07-20	2006-03-30	Sandor Molnar	Processes for preparation of crystalline mycophenolate sodium
CN100383520C (zh) *	2004-09-20	2008-04-23	复旦大学	一种测定人血浆中霉酚酸及其代谢物的方法
WO2006086500A2 (en) *	2005-02-08	2006-08-17	Aspreva Pharmaceuticals Sa	Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) *	2005-02-08	2006-10-19	Richard Glickman	Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20080280977A1 (en) *	2005-04-26	2008-11-13	Sandor Molnar	Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2008000418A2 (en)	2006-06-27	2008-01-03	Sandoz Ag	New method for salt preparation
CN101953807A (zh) *	2010-10-09	2011-01-26	山西普德药业有限公司	一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
BR112015022854A2 (pt)	2013-03-14	2017-07-18	Alkermes Pharma Ireland Ltd	pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en)	2013-06-27	2015-10-27	Veloxis Pharmaceutical A/S	Regimen for suppressing organ rejection
JP6337135B2 (ja)	2014-02-24	2018-06-06	アルカーメスファーマアイルランドリミテッド	フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US11918684B2 (en)	2017-03-13	2024-03-05	Liqmeds Worldwide Limited	Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2020039263A2 (en)	2018-08-18	2020-02-27	Ftf Pharma Private Limited	Pharmaceutical suspension for oral dosage
CA3212370A1 (en)	2021-03-03	2022-09-09	Sana Biotechnology, Inc.	Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4328213A (en) *	1979-11-28	1982-05-04	Schering Corporation	Stable injectable labetalol formulation
US4478829A (en) *	1983-04-28	1984-10-23	Armour Pharmaceutical Company	Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) *	1984-02-20	1996-09-20	Ф.Ю. Рачинский	Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) *	1987-01-30	1988-06-28	Syntex (U.S.A.) Inc.	Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) *	1989-11-06	1991-05-10	Adir	Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

1994
- 1994-09-12 PL PL94313480A patent/PL178522B1/pl unknown
- 1994-09-12 NZ NZ273801A patent/NZ273801A/en not_active IP Right Cessation
- 1994-09-12 BR BR9407469A patent/BR9407469A/pt not_active Application Discontinuation
- 1994-09-12 CN CN94193413A patent/CN1060770C/zh not_active Expired - Lifetime
- 1994-09-12 EP EP94928054A patent/EP0724581B1/en not_active Expired - Lifetime
- 1994-09-12 RU RU96107396A patent/RU2132849C1/ru active
- 1994-09-12 RO RO96-00567A patent/RO118075B1/ro unknown
- 1994-09-12 SI SI9420052A patent/SI9420052B/sl unknown
- 1994-09-12 CZ CZ1996788A patent/CZ292423B6/cs not_active IP Right Cessation
- 1994-09-12 RO ROA200201154A patent/RO118427B1/ro unknown
- 1994-09-12 CA CA002171836A patent/CA2171836C/en not_active Expired - Lifetime
- 1994-09-12 WO PCT/US1994/010142 patent/WO1995007902A1/en not_active Ceased
- 1994-09-12 JP JP50925595A patent/JP3411038B2/ja not_active Expired - Lifetime
- 1994-09-12 HU HU9600652A patent/HU217300B/hu unknown
- 1994-09-12 SG SG1996001679A patent/SG55006A1/en unknown
- 1994-09-12 DK DK94928054T patent/DK0724581T3/da active
- 1994-09-12 AT AT94928054T patent/ATE173475T1/de active
- 1994-09-12 AU AU77238/94A patent/AU677435B2/en not_active Expired
- 1994-09-12 DE DE69414720T patent/DE69414720T2/de not_active Expired - Lifetime
- 1994-09-12 KR KR1019960701354A patent/KR100349772B1/ko not_active Expired - Lifetime
- 1994-09-12 ES ES94928054T patent/ES2123831T3/es not_active Expired - Lifetime
- 1994-09-14 ZA ZA947088A patent/ZA947088B/xx unknown
- 1994-09-14 IL IL11097094A patent/IL110970A/en not_active IP Right Cessation
- 1994-09-14 PH PH48985A patent/PH30685A/en unknown
- 1994-09-14 TW TW083108484A patent/TW370527B/zh not_active IP Right Cessation
- 1994-12-05 US US08/349,236 patent/US5543408A/en not_active Expired - Lifetime
- 1994-12-09 UA UA96031026A patent/UA49797C2/uk unknown
1995
- 1995-06-02 US US08/459,991 patent/US5545637A/en not_active Expired - Lifetime
1996
- 1996-03-13 FI FI961169A patent/FI119639B/fi not_active IP Right Cessation
- 1996-03-15 NO NO19961075A patent/NO314727B1/no not_active IP Right Cessation
- 1996-03-15 LV LVP-96-85A patent/LV11326B/en unknown
- 1996-03-15 LT LT96-028A patent/LT4052B/lt not_active IP Right Cessation
1997
- 1997-12-05 MX MXPA94007099A patent/MXPA94007099A/es active IP Right Grant

Also Published As

Publication number	Publication date
HU217300B (hu)	1999-12-28
WO1995007902A1 (en)	1995-03-23
JP3411038B2 (ja)	2003-05-26
IL110970A0 (en)	1994-11-28
CN1060770C (zh)	2001-01-17
AU7723894A (en)	1995-04-03
HU9600652D0 (en)	1996-05-28
FI961169A0 (fi)	1996-03-13
NZ273801A (en)	1997-10-24
CA2171836C (en)	2006-11-14
TW370527B (en)	1999-09-21
NO961075D0 (no)	1996-03-15
DE69414720D1 (de)	1998-12-24
CN1131420A (zh)	1996-09-18
JPH09502721A (ja)	1997-03-18
HK1012624A1 (en)	1999-08-06
LT4052B (en)	1996-10-25
UA49797C2 (uk)	2002-10-15
CZ78896A3 (en)	1996-10-16
CA2171836A1 (en)	1995-03-23
FI119639B (fi)	2009-01-30
RO118075B1 (ro)	2003-01-30
BR9407469A (pt)	1996-11-12
ZA947088B (en)	1996-03-14
IL110970A (en)	1999-01-26
US5543408A (en)	1996-08-06
KR100349772B1 (ko)	2002-12-28
NO961075L (no)	1996-03-15
AU677435B2 (en)	1997-04-24
FI961169L (fi)	1996-03-13
LT96028A (en)	1996-08-26
PL178522B1 (pl)	2000-05-31
LV11326A (lv)	1996-06-20
RU2132849C1 (ru)	1999-07-10
CZ292423B6 (cs)	2003-09-17
SG55006A1 (en)	1998-12-21
DE69414720T2 (de)	1999-04-08
ES2123831T3 (es)	1999-01-16
HUT75119A (en)	1997-04-28
PL313480A1 (en)	1996-07-08
EP0724581B1 (en)	1998-11-18
RO118427B1 (ro)	2003-05-30
MXPA94007099A (es)	2004-01-23
EP0724581A1 (en)	1996-08-07
PH30685A (en)	1997-09-16
NO314727B1 (no)	2003-05-12
SI9420052A (en)	1996-12-31
ATE173475T1 (de)	1998-12-15
SI9420052B (sl)	2004-02-29
US5545637A (en)	1996-08-13
LV11326B (en)	1996-10-20

Publication	Publication Date	Title
DK0724581T3 (da)	1999-08-02	Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf
NO971889L (no)	1997-06-23	Forbindelser og sammensetninger for levering av aktive midler
DE69427704D1 (de)	2001-08-16	Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
CA2171275A1 (en)	1996-09-08	Stilbene derivatives and pharmaceutical compositions containing them
DE19875032I2 (de)	2007-04-19	Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen
MY100359A (en)	1990-08-28	External pharmaceutical composition.
CA2108903A1 (en)	1992-11-04	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA922297B (en)	1992-12-30	Crystalline tiababine monohydrate,its preparation and use
GEP20032953B (en)	2003-04-25	Antitumor Agents
DE68929368D1 (de)	2002-02-21	Cephemderivate und Verfahren zu ihrer Herstellung
DE69108408D1 (de)	1995-04-27	4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung.
ATE35812T1 (de)	1988-08-15	Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
TW252979B (da)	1995-08-01
NO931011L (no)	1993-10-04	7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
WO1990003172A3 (en)	1990-06-28	Bile acids for treatment of viral infections
GEP20033054B (en)	2003-08-25	2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
EP0127389A3 (en)	1985-08-07	N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
EP0583480A4 (en)	1994-03-18	Side-effect alleviant.
ES2076517T3 (es)	1995-11-01	Ergolinas disustituidas en posiciones 2,13, su preparacion y utilizacion en medicamentos.
GT199300041A (es)	1994-12-30	Derivados de hidrazona, proceso para producir los mismos, insecticidas y/o acaricidas que contienen dichos derivados co-mo ingrediente activo y compuestos intermedios para producir dichos derivados.